Nevertheless, new observations of the effect of GLP-1 agonists in individuals with both type-2 diabetes and COPD suggest beneficial effects of weight loss, including a lower risk of severe exacerbations.41 This evidence concerns the gene GCG and type 2 diabetes mellitus.